Latest News and Press Releases
Want to stay updated on the latest news?
-
CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the United States District Court for the District of Delaware has found each of...
-
-- New collaboration and license agreement with CSL to develop Fc multimer programs, including M230, with a $50M upfront license fee -- -- Agreement with Shire to receive full rights to M923 and a...
-
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL-- ...
-
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
-
CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA®...
-
CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
-
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate-- CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta...
-
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced...
-
CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
-
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...